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Abstract
Background: Undergoing an extraction has been shown to pose a significantly increased risk for the development
of chronic apprehension for dental surgical procedures, disproportionate forms of dental anxiety (that is, dental
phobia), and symptoms of post-traumatic stress. Evidence suggests that intrusive emotional memories of these
events both induce and maintain these forms of anxiety. Addressing these problems effectively requires an
intervention that durably reduces both the intrusiveness of key fear-related memories and state anxiety during
surgery. Moreover, evidence suggests that propranolol is capable of inhibiting “memory reconsolidation” (that is, it
blocks the process of storing a recently retrieved fear memory). Hence, the purpose of this trial is to determine the
anxiolytic and fear memory reconsolidation inhibiting effects of the ß-adrenoreceptor antagonist propranolol on
patients with high levels of fear in anticipation of a dental extraction.
Methods/Design: This trial is designed as a multicenter, randomized, placebo-controlled, two-group, parallel,
double-blind trial of 34 participants. Consecutive patients who have been referred by their dentist to the departments
of oral and maxillofacial surgery of a University hospital or a secondary referral hospital in the Netherlands for at least
two tooth and/or molar removals and with self-reported high to extreme fear in anticipation of a dental extraction
will be recruited. The intervention is the administration of two 40 mg propranolol capsules 1 hour prior to a dental
extraction, followed by one 40 mg capsule directly postoperatively. Placebo capsules will be used as a comparator.
The primary outcome will be dental trait anxiety score reduction from baseline to 4-weeks follow-up. The secondary
outcomes will be self-reported anxiety during surgery, physiological parameters (heart rate and blood
pressure) during recall of the crucial fear-related memory, self-reported vividness, and emotional charge
of the crucial fear-related memory.
Discussion: This randomized trial is the first to test the efficacy of 120 mg of perioperative propranolol versus placebo
in reducing short-term (“state”) anxiety during dental extraction, fear memory reconsolidation, and lasting dental (“trait”)
anxiety in a clinical population. If the results show a reduction in anxiety, this would offer support for routinely
prescribing propranolol in patients who are fearful of undergoing dental extractions.
Trial registration: ClinicalTrials.gov identifier: NCT02268357, registered on 7 October 2014. The Netherlands National
Trial Register identifier: NTR5364, registered on 16 August 2015.
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Background
Epidemiology and current management of fear for
dental extractions
Tooth or molar removals are among the most strongly
feared procedures in Dentistry and Oral and Maxillofacial
Surgery [1, 2]. In the United States, approximately 55
million extractions and surgical removals are carried out
each year [3]. In the majority of cases, having a tooth
removed causes immediate but generally transitory
emotional distress [4–7]. This type of transitory (“state”)
anxiety not only produces discomfort but can also induce
patient behavior that impedes surgery, thereby increasing
operative time and complicating postoperative recovery
[8, 9]. Hence, to be capable of effectively performing
dental treatment, Oral and Maxillofacial surgeons and
specialized dental fear clinics commonly employ oral and
intravenous sedatives such as benzodiazepines and nitrous
oxide. However, the application of conscious sedation
requires thorough training, and sedation-related incidents
are common [10]. A publication by the National Health
Service of the United Kingdom showed that, in the period
between 2004 to 2008, 1,529 incidents were reported
regarding conscious sedation with midazolam; in three
cases, the patient died [10]. Further disadvantages of
these agents include reduced cognitive and motor
function, and anterograde amnesia, which may inter-
fere with long-term anxiety reduction [11, 12]. More-
over, to date, only limited evidence exists for the
effectiveness of these agents at reducing dental anx-
iety [13]. Because anxiety treatment failure rates of 88
to 91 % for intravenous sedation and 61-70 % for
nitrous oxide have been found at 1-year follow-up
after treatment [14], new safe, easily applied and cost-
effective interventions for use within the dental and
oral surgical setting are warranted.
Role of traumatic dental experiences in the etiology and
maintenance of dental anxiety
Having undergone an extraction had been found to pose an
increased risk for developing persistent anxiety [6, 7, 15]. A
small portion of approximately 4 to 8 % of patients
suffer from elevated dental trait anxiety or even post-
traumatic stress disorder (PTSD) symptoms 1 month
after surgical removal of their wisdom teeth [6, 7].
This suggests that the psychological impact of a dental
extraction may not be limited to temporary distress but
also that a dental extraction is a potential psychologically
traumatic experience to at least some patients.
A wide array of studies have shown that dental fear
and anxiety are deeply rooted in the experience of previ-
ous negative dental or other types of distressing and
traumatic life events, for example, [15–18]. A recent
case-control study (total n = 153) among dental phobic
individuals, subthreshold dental phobics and normal
controls, showed that apprehension of dental treatment
is strongly associated with the presence of memories
of earlier distressing events [19]. For example, 97 %
of subthreshold (non)phobic individuals have reported
a memory of an aversive event, predominantly in the
dental setting, that initiated or exacerbated their
dental anxiety; this was significantly higher than the
proportion of normal controls reporting such a mem-
ory [19]. Emotional disturbance, vividness and sense
of reliving of these memories were significantly higher
in the subthreshold phobic group and dental phobic
group than in the normal controls [19]. Notably, nor-
mal controls reported lower levels of intrusiveness
and avoidance scores (features typically seen in indi-
viduals suffering from PTSD) than both phobic and
subthreshold phobic groups (all p values < 0.001). This
suggests that the memories of the previous distressing
dental events that initiated the dental fear play an
important role in the maintenance of the individual’s
current anxiety and fear response [19]. This is of
importance, as research has indicated that dental
anxiety is likely to lead to avoidance of dental care
with subsequent adverse effects on oral health status
and quality of life [20].
Rationale for testing the effects of perioperative
propranolol on dental anxiety
Treating apprehension or fear of dental treatment effect-
ively requires an intervention that reduces the (1) state
anxiety during the surgery, (2) the emotional charge of key
fear-related memories, and (3) patients’ level of dental trait
anxiety. There are indications that the ß-blocker propran-
olol is capable of bringing about these anxiolytic effects.
Propranolol, a ß1,2-adrenoreceptor antagonist, competes
at the receptor level with catecholamines, thereby blocking
their orthosympathetic effects [21]. Clinically, propranolol
is used widely to target peripheral sites of the noradrener-
gic system to treat hypertension [22], coronary artery
disease [23] and tachyarrhythmias [24]. In addition, pro-
pranolol can be deployed to block ß-adrenoreceptors in
the central nervous system, as the lipophilic compound
readily enters the blood-brain-barrier.
Several trials studying off-label use of propranolol have
been conducted, such as its application in the treatment
of high levels of trait anxiety [25–27], substance disorder
and withdrawal symptoms [28], schizophrenia [29],
autism [30], and aggression [31]. In addition, propran-
olol has been shown to mitigate milder distressing states
such as exam nerves [32–34], stage fright [35], perform-
ance anxiety among musicians [36] and surgeons [37],
and fear of undergoing surgery [38–40]. Evidence
suggests that propranolol positively influences dental
state anxiety and reduces the storage of fear memories.
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Evidence for effects of propranolol on dental state anxiety
Currently one randomized, controlled clinical trial (RCT)
evaluating the state anxiolytic effects of propranolol in
dental phobia has been published. It showed that, as
compared to placebo, 80 to 120 mg of oral propranolol
significantly diminished self-reported state anxiety during
injection of local dental anesthesia (self-reported anxiety
about the injection: 5.5 (2.75) versus 7.45 (2.0), p = .033,
one-tailed) [41]. A limitation to this study is that
follow-up data were lacking. This means that to date,
the long-term effects of propranolol on dental trait
anxiety are unknown.
Evidence for effects of propranolol on fear memory storage
Because traumatic memories seem to play a key role in
the maintenance and severity of dental trait anxiety [19],
propranolol has potential for the treatment of this con-
dition. Preclinical studies have shown that propranolol
has the capacity to selectively block the protein syn-
thesis required for the storage of aversive (emotional)
memory while sparing declarative memory (factual
memory) [42–50]. A recent meta-analysis of eight experi-
ments with healthy human volunteers (total n = 308)
supports this line of reasoning, as it showed that,
compared to placebo, propranolol administered before
memory reactivation reduces the expression of cue-elicited
fear responses [51]. To date however, there is only one
clinical trial supporting the effects of propranolol on the
reconsolidation of traumatic memories. In this study, with
chronic PTSD patients (n = 19), it was found that 40 mg of
short-acting oral propranolol given prior to imaginary
exposure to the disturbing memory of the event, followed
by 60 mg of long-acting oral propranolol, significantly
reduced physiologic responding to the memory one week
later [52]. Although preclinical evidence is promising,
clinical evidence is scarce. Therefore, the reconsolida-
tion blocking capacities of propranolol need further
research attention.
Primary aim
The primary aim of this study is to determine whether
administration of the active substance (two 40 mg
propranolol capsules 1 hour prior to dental extraction,
followed by one 40 mg capsule immediately postopera-
tively) results in a significantly greater reduction of dental
trait anxiety in patients with self-reported high to extreme
fear in anticipation of dental extraction, compared to the
effects of the placebo comparator, from baseline to 4-week
follow-up appointment.
Secondary aims
The secondary aims are to determine whether the use of
propranolol in patients with high self-reported levels of
fear in anticipation of tooth or molar removal results in
the following:
1) a significantly greater reduction of self-reported
intraoperative (state) anxiety, compared to the
placebo comparator, from baseline to the 4-week
follow-up appointment;
2) a significantly greater decrease of physiological
responding during recall of the crucial fear-related
memory, compared to the placebo comparator, from
baseline to the 4-week follow-up appointment;
3) a significantly greater decrease in specific phobia
diagnoses, compared to the placebo comparator,
from baseline to the 4-week follow-up appointment;
4) a significantly greater reduction of self-reported
vividness and emotional charge of the crucial
fear-related memory scores, compared to the
placebo comparator, from the baseline to the
4-week follow-up appointment.
Methods/Design
Trial design
The trial is designed as a multicenter, randomized,
placebo-controlled, two-group, parallel, double-blind
superiority trial of 34 participants with an allocation
ratio of 1:1.
Study population
Adult participants of all genders will be recruited from
the waiting list of patients referred to the departments of
Oral and Maxillofacial Surgery of the Academic Medical
Center of the University of Amsterdam (AMC), the
Netherlands, and the department of Oral and Maxillofacial
Surgery of the Spaarne Gasthuis Hospital in Haarlem,
the Netherlands, by their dentists. Participants have
an indication for the removal of at least two teeth
and/or molars, and indicate finding a tooth or molar
removal highly or extremely anxiety provoking.
Eligibility criteria
Inclusion criteria
The inclusion criteria are as follows:
1. Signed written informed consent
2. Minimum age of 18 years on entry to the study
3. Self-reported high to extreme fear of tooth or
molar removal
4. Dutch or English-speaking
Exclusion criteria
The exclusion criteria include the following:
1. Asthma or other obstructive pulmonary disease
2. Cardiac failure
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3. Cardiac arrhythmia
4. Renal failure
5. Insulin-dependent diabetes mellitus
6. Pregnant or breast-feeding
7. Current use of another ß-adrenoreceptor antagonist
8. Current use of anxyiolytic or antidepressant medication
9. Currently in psychotherapy for dental anxiety
10. Systolic blood pressure < 100 mmHg
Sample size calculation
A power analysis was performed for the primary out-
come variable, dental trait anxiety as indexed by the
Short-version of the Dental Anxiety Inventory (S-DAI).
In order to detect a difference between the propranolol
and control condition on changes in dental anxiety scores
over time, a two-way (one-within and one-between sub-
jects factor) repeated measures ANOVA will be used.
Using G*Power 3.0 software, assuming a correlation of
0.50 between two repeated measurements, a medium size
treatment effect (f = 0.25), a power of 0.80, an α signifi-
cance level of 0.05, and two treatment conditions, the
power analysis results in a total sample size of 34 persons.
Study procedures
The study procedures and participant flow through each
stage are summarized in a flow-chart (Fig. 1).
Screening and recruitment
Potential participants will be recruited from the waiting
list of consecutive patients referred to the Department
of Oral and Maxillofacial Surgery of the Academic
Medical Center of the University of Amsterdam, the
Netherlands, and the Department of Oral and Max-
illofacial Surgery of the Spaarne Gasthuis Hospital in
Haarlem, the Netherlands, by their dentists. The
patients have an indication for the removal of at least
two teeth and/or molars. They will be contacted by
the investigators by telephone, and informed about
the trial. After a short introduction, they will be
asked to rate how anxiety provoking a tooth or molar
removal is to them on a four-point scale (translated
from Dutch); “not anxiety provoking at all” (1), “more
or less anxiety provoking” (2), “fairly/highly anxiety
provoking” (3), or “extremely anxiety provoking” (4).
When patients indicate that a score of 3 or 4 applies
to them, they will be asked whether they are inter-
ested in receiving a potential participant information
letter at their home address. The patients will be
offered the opportunity to contact an independent
physician for questions regarding their participation.
No financial or other form of compensation is
provided for participation.
Informed consent
After patients have had sufficient time to reflect and
decide to give written informed consent, they will be
registered as participants in the trial.
First preoperative assessment
Participating patients will be asked to arrive at the waiting
room of both outpatient Oral and Maxillofacial surgery
clinics, 1 hour and 15 minutes prior to their appointment
for ingestion of study medication, for a diagnostic inter-
view and filling out questionnaires. Demographic variables
(age, sex, highest level of education marital status, and
country of birth) will be recorded.
Next, the presence of specific (that is, dental phobia in
accordance with the DMS-IV TR criteria updated in
2000 [53] will be assessed using the Phobia Checklist
containing four questions based on the DSM-IV TR
criteria, developed for the assessment of dental phobia
[54]. The Phobia Checklist contains four questions based
on the Diagnostic and Statistical Manual of Mental
disorders, text revision (DSM-IV TR) [53] criteria for
specific phobia, developed for the assessment of dental
phobia [54]. The Phobia Checklist has been validated
and proven to be a valid diagnostic tool for this purpose
(sensitivity = 0.95, specificity = 0.99, and an overall hit
rate of 97 %). The presence of specific (that is, dental)
phobia in accordance with the DSM 5 criteria updated
in 2013 [55] will be indexed using an adapted version of
The Mini International Neuropsychiatric Interview Plus,
Dutch version 5.0.0 section “Specific phobia” (H). The
MINI-Plus [56] is a structured diagnostic interview to
systematically assess DSM-IV and 10th revision of the
International Classification of Diseases and Related
Health Problems (ICD-10) diagnoses. A recent version
of the MINI-Plus is not available; therefore, an adapted
version will be used in which the new DSM 5 criteria
[55] are addressed. Since only the presence of a specific
phobia is of interest, only the section “Specific phobia”
(H) will be used to assess the dichotomous specific
phobia outcome.
To identify the memories of distressing events that
initiated or exacerbated dental anxiety, the Full Intrusions
Interview, a modified semi-structured interview adapted
from Reynold and Brewin (1999) [57] will be used.
Patients will be asked to report any spontaneous autobio-
graphical memory that kept coming to mind over the
previous week from a past event. If the last week had been
exceptional, they will be prompted to think back to a typ-
ical week, or a week shortly before a dental appointment.
The participant will be requested to identify the most
disturbing memory. Based on this memory, the investiga-
tor will compose and record an approximately 30-second
personal memory script, portraying the experience. This
script of the most crucial traumatic memory is called M1.
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Fig. 1 Flow-chart of study procedures
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Characteristics of this memory will be subsequently
determined (that is, avoidance and aversiveness pro-
pensity, the sense of here and now, the impact of and
burden caused by the memory), after which patients
will be requested to rate these characteristics on
standardized continuous self-report VASs ranging
from 0 to 100.
Treatment allocation
After the interview, patients will be randomized and
allocated to receive either perioperative oral propranolol
capsules or placebo capsules. Both groups will undergo
two regular dental extraction procedures, with a 4-week
interval.
First dental extraction procedure
One hour and 15 minutes before the surgery, participants
will be approached by the investigator. They will then
receive the first two capsules of study medication. The
intervention group will receive 80 mg of oral propranolol
(2 capsules) 1 hour and 15 minutes prior to treatment,
and 40 mg of oral propranolol (1 capsule) directly after
treatment. The control group will receive oral placebo
capsules in the same order. The following hour is reserved
to allow time for achieving an optimal plasma concentra-
tion of propranolol.
In the period between ingestion of the study medication
and the surgery, a 30-minute screening by an investigator
will take place (see paragraph: “Study outcome measures”).
All outcomes will be registered on a case report form
(CRF). After the interview, the patients will be guided
back to the waiting room by the investigator. Next, they
will be invited into the operating room by their surgeon.
The surgeon will be either a senior staff member or a resi-
dent in Oral and Maxillofacial Surgery. During this first
procedure, a prilocaine 3 % with felypressin (1:850,000)
solution will be administered as local intraoral anesthetic
to prevent a possible unwanted α-pressor reaction; a rare
and potentially harmful pharmacological interaction of
ß-adrenoreceptor antagonists with adrenaline that may
result from the intravascular injection of the local
anesthetic, causing bradycardia and hypertension.
In case of patients with a high level of fear of dental
extractions, the surgeon will be notified that the patient
has a “high or extreme” fear of dental extractions (the
level of fear is not specified further) and is instructed to
treat the patients accordingly.
First postoperative assessment
At completion of the surgical procedure, the dental
surgeon will fill out the CRF containing the operative
variables. Before leaving the clinic, the patient will again
be shortly interviewed by the investigator. Only after the
first dental extraction procedure will another semi-
structured interview be conducted. This is meant to
construct an approximately 30-second personal memory
script portraying this first dental extraction procedure
that the participant has just experienced (M2). The
participant will subsequently receive one final capsule con-
taining 40 mg of propranolol or placebo. The participant
will be asked to fill in a small “intrusions diary” at home.
Second dental extraction procedure
At the 1-month follow-up, a second dental extraction at
the hospital will be performed, this time without the
study medication. Administration of all questionnaires
before and after the procedure will be repeated, but this
time, no full-intrusions interview will be conducted.
During the second procedure, a regularly used local
anesthetic solution of articaine 4 % with adrenaline
(1:200,000) will be administered. At completion, the
surgeon will fill out another CRF, and the participant will
be asked to keep another “intrusions diary”.
Methods to maximize participant adherence to the
intervention and follow-up procedures
The day before the first and second treatment, partici-
pating patients will receive a text message on their cell
phone and an email at their home address reminding
them of the appointments. The day after the first and
second treatment, participants will receive another
text message or email reminding them to fill out the
“intrusions diary”.
Investigational products
Active substance
The active medicinal product investigated is Propranolol
HCl (a lipophilic ß1,2-adrenoreceptor antagonist) 3 x 40
mg tablets overencapsulated in three blue-white, size 00,
oral capsules, complemented with microcrystalline cellu-
lose PH 102.
The preoperative dose of 80 mg propranolol is intended
to mitigate perioperative state anxiety. Previous research
has shown that a dose of 40 mg of oral propranolol was
inadequate to reduce the acute hyperadrenergic anxiety
states in recently psychologically traumatized individuals
[58], and that administration of 80 to 120 mg of oral
propranolol significantly reduced self-reported anxiety
during injection of local intraoral anesthesia in patients
with dental phobia [41].
The administration of 40 mg of propranolol immedi-
ately postoperatively is targeted at blocking the reconsoli-
dation process of emotional memory. Research suggests
that a “window of opportunity” for ß-adrenergic modula-
tion of memory reconsolidation exists for some hours
after retrieval of a fear-related memory [50, 59]. Because
propranolol has a half-life of approximately 4 hours, the
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initial preoperative dose may not exert sufficient ß-adren-
ergic receptor antagonizing effects during the full recon-
solidation period.
Placebo comparator
The placebo comparators are three capsules, visually
identical to the active substance, filled with pharmaco-
logically inactive microcrystalline cellulose PH 102 as a
sole ingredient.
Sequence generation, allocation concealment and
implementation
The random allocation sequence will be computer-
generated. The allocation list is available only to the GMP-
certified Hospital Pharmacy, where the study medication
was produced and labeled, and to the Hospital Pharmacies
of both study locations, where the study medication is
conserved and provided. The manufacturer of the inves-
tigational medicinal products (GMP-certified Hospital
Pharmacy) will randomize the allocation sequence;
bottles consecutively issued by the study pharmacies
will therefore contain either propranolol or placebo
capsules in a random order.
Blinding
Trial participants, investigators, data collectors, the
statistician, and outcome assessors are blinded to the
study-group assignments. Only the producing and
providing hospital pharmacy staff are not blinded; the
allocation of a participant will be unmasked before the
end of the trial only in case of a serious adverse event
related to the study medication.
Study outcome measures
Dependent variables were derived from the questionnaires
listed below (see Tables 1 and 2).
Primary outcome measure
The primary aim is to assess the reduction in the dental
trait anxiety score in the propranolol versus the placebo
control group (Table 1). The change from baseline to
1-month follow-up in dental trait anxiety will be
indexed with the Dutch version of the Short version of the
Dental Anxiety Inventory (S-DAI) [60]. The items (for
example, “when I know the dentist/oral-maxillofacial
surgeon is going to extract a tooth, I am already afraid in
the waiting room”) are answered on a five-point Likert-
type scale, ranging from “totally not applicable to me” (1)
to “totally applicable to me” (5). Total scores on this ques-
tionnaire range from 9 to 45. The clinical cut-off score for
a patient to apply for treatment in a specialized dental fear
clinic is a minimum of 28 points on the S-DAI [61].
Table 1 Primary and secondary study outcome measures
Measures
Primary outcome Secondary outcomes
Trait anxiety (S-DAI) State anxiety
(VAS score)
Vividness/emotional charge
(M1) propensity (VAS scores)
Physiological response
(HR/BP)
Screening (t = 0) Screening interview
Intervention (t = 1) Preoperative interview X X X
Postoperative interview X
Follow-up (t = 2) Preoperative interview X X X
Postoperative interview X
Note: BP blood pressure, HR heart rate, M1 crucial fear-related memory, S-DAI Short version of the Dental Anxiety Inventory, VAS visual analog scale
Table 2 Tertiary outcome measures
Measures
Operative variables/
qualitative aspect
of the surgical
experience (VASs)
Test of
blind
IES FCDS Qualitative aspect
of memory
M2 (VASs)
Qualitative aspect
of memory
M1 (VASs)
Intrusions
diary
Specific
phobia
diagnosis
Screening (t = 0) Screening interview X X
Intervention (t = 1) Preoperative interview X X
Postoperative interview X X X X
Follow-up (t = 2) Preoperative interview X X X X X
Postoperative interview X X
Notes: FCDS fear of stimuli compromising the dental setting, IES Impact of Event Scale - Revised, M1 crucial fear-related memory, M2 memory of recent dental
extraction procedure, VAS visual analog scale
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Secondary outcome measures
The self-reported state anxiety during dental treatment
from baseline to 1-month follow-up will be indexed
using a visual analog scale (Table 1). Patients are asked
to rate the question “How much anxiety did you experi-
ence during the last treatment” using a standardized
continuous self-report VAS ranging from “no anxiety at
all” 0 to “extreme anxiety” 100.
Change from baseline to 1-month follow-up in self-
reported vividness and emotional charge of the crucial
fear-related memory will be measured using visual ana-
log scales that assess key characteristics of the traumatic
memory that initiated or exacerbated the dental anxiety
(M1) (Table 1). Patients will be asked to rate the ques-
tions “how vivid or detailed is the memory, if you bring
up the memory now” and “how much emotion does the
memory evoke, if you bring up the memory now” using
a continuous self-report VAS ranging from “no (anxiety/
emotion) at all” (0) to “extremely much (anxiety/emo-
tion)” (100).
Change from baseline to 1-month follow-up in physio-
logical parameters during recall of the crucial fear-related
memory (M1), will be assessed by bringing up the mem-
ory (M1) while the psychophysiological response (heart
frequency per minute and blood pressure in mm Hg) will
be indexed using an upper arm blood pressure measuring
device (CE: 0297) (Table 1).
Tertiary outcome measures
The frequency of post-traumatic stress symptoms will be
assessed using the Dutch version of the Impact of Event
Scale (IES) [62]. The IES is a 15-item self-report scale,
measures the subjective stress following a traumatic
event and is one of the most widely used self-report
instruments of symptoms of post-traumatic stress [63].
It assesses three PTSD symptom subscales: (1) the
intrusion (that is, the loss of voluntary control over
the regulation of thoughts) subscale, (2) the avoidance
(for example, the extent to which memories are con-
sciously suppressed) subscale, and (3) the hyperarousal
subscale. Items (for example, “pictures about it popped
into my mind”) are rated on a four-point scale of
frequency, ranging from “not at all” (0), “rarely” (1),
“sometimes” (3), to “often” (5). The scores are summarized
to produce a range of 0 to 75 for the total score. Patients
will be explicitly instructed to fill out the IES related to
the crucial traumatic memory that exacerbated or initiated
their dental anxiety (M1). A score of 26 is considered the
cut-off point for a clinically significant level of trauma-
related symptomatology [64].
The fear of objects and situations related to the
dental setting will be assessed using the Fear of
Stimuli Compromising the Dental Setting (FCDS)
questionnaire. This questionnaire includes the 25 most
prevalent stimuli among 67 anxiety-provoking stimuli
found in a study in 960 Dutch adults [1]. The fear provok-
ing nature of each item will be scored on a four-point
scale, from “not at all fear provoking” (1), to “extremely
fear provoking” (4).
During the semi-structured interviews after the first
and before the second dental extraction procedure,
qualitative aspects of the memory for the recent dental
extraction [M2] will be assessed (that is, vividness, emo-
tional charge, avoidance and aversiveness propensity,
sense of here and now, the impact of and burden caused
by the memory). Patients will be asked to rate these
characteristics on standardized continuous self-report
VASs, ranging from 0 (for example, “not aversive at all”)
to 100 (for example, “extremely aversive”).
The weeks after the dental extractions, the frequency
and nature of intrusive thoughts will be indexed using
an intrusions diary. Study participants will be asked to
record their frequency and nature of their thoughts of
the crucial traumatic event that exacerbated or initiated
their dental anxiety (M1) for 7 days following the first
and second dental extraction procedure.
A number of specific memory characteristics regarding
the event that exacerbated or initiated their dental anx-
iety (M1) will be assessed using a 16-item self-report
Memory Characteristics Questionnaire (MCQ), on two
subscales; re-experiencing (eight items), disorganization
(six items), peritraumatic dissociation (one item) and
depersonalization and/or derealization during memory
retrieval (one item) [65]. All 16 items are rated on a
four-point scale ranging from “never” (0) to “all the
time” (3).
The patients’ experiences during surgery will be
assessed using visual analog scales (ranging from 0 to
100). Directly after the first and second (follow-up) den-
tal extraction procedure, characteristics of participants’
experiences during surgery will be determined. Patients
will be asked to rate the propensity of pain experi-
enced during treatment, the degree of experienced
reassurance/comforting by their surgeon, the sense of
“here and now” when thinking back at this experience
and how pleasurable the experience was. Patients will
be asked to rate these characteristics on standardized
continuous self-report VASs ranging from 0 (for
example, “not reassured at all”) to 100 (for example,
“completely reassured”).
Operative variables
A number of operative variables will be recorded by the
surgeon after the first and second dental extraction
procedure. These include the nature of the procedure
(extraction/surgical removal; numbering of the dental
elements extracted using the FDI World Dental Feder-
ation/ISO 3950:2009 notation), duration of the surgery,
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difficulty (that is, whether the surgery was experienced
as a “complicated procedure”), number and location of
anesthetic capsules administered, observer-rated anxiety
(surgeons are asked to rate the question “according to
you, how much anxiety did the patient show during
treatment” using a continuous observer-rated VAS
ranging from (0) “no anxiety at all” to (100) “extremely
anxious”), nature of the follow-up treatment, and infor-
mation on the occurrence of any adverse events.
Test of blindness
The patients’ blindness to treatment allocation will be
assessed, with respect to the possibility of subsequent
biased psychological or physical responses to the inter-
vention. To this end, after all the study medication has
been ingested following the first dental extraction,
participants will be asked to answer the multiple-choice
question “do you think that you have received: (a) the
“real” capsules (with propranolol) or (b) the “fake
capsules” (with placebo)” with either (a) or (b).
Data management
To ensure data security and confidentiality, the coded
anonymous case report forms will be stored in a locked
room to which only the assessors have access.
Statistical analysis plan
The distributions of demographic variables and quantita-
tive data will be displayed in tables. Associations between
categorical variables will be analyzed using the Chi2-test.
Differences between the propranolol and placebo con-
dition on continuous variables will be analyzed using
the independent-samples t-test. Two-way (condition
by time) repeated measures ANOVA will be used to
compare the propranolol and placebo condition on
the dental anxiety reduction between the first and
second extraction, possibly with the baseline score as
a covariate (if differences exist at baseline). The alpha
is set at a significance level of 5 %.
Ethical approval
This trial (protocol number NL42210.018.13) is being
performed in accordance with the Declaration of Helsinki
[66] and received ethical approval by the Institutional
Review Board “Medisch Ethische Toetsingscommissie
Academisch Medisch Centrum” (Medical Ethics Commit-
tee of the Academic Medical Center in Amsterdam, the
Netherlands) on July 24, 2014. The present study protocol,
version 5 (April 1, 2015), has received ethical approval by
the latter Institutional Review Board on April 20, 2015.
Plans for important protocol modifications will be
communicated to the Institutional Review Board, Clinical-
Trials.gov and the Netherlands National Trial Register.
Safety monitoring
In order to (1) protect the rights and well-being of
human subjects; (2) ensure that trial data are accur-
ate, complete and verifiable from source documents;
and (3) ascertain that the conduct of this trial is in
compliance with the currently approved protocol, with
Good Clinical Practice (GCP), and with applicable
regulatory requirements, this clinical trial is being
monitored by a GCP-trained, independent monitor,
who is not involved in the clinical trial as part of the
trial staff. The monitor will report findings before,
during and after the trial.
Harms
Every adverse event related to the study intervention will
be reported on the case report form by the dental
surgeon. Participants are insured for harm during and
within four years after the end of the trial.
Discussion
We present a study protocol for a randomized controlled
trial to test the effectiveness of 120 mg of perioperative
propranolol versus placebo to reduce dental trait anxiety,
state anxiety during surgery, as well as physiological
responses and memory intrusiveness during recall of a
crucial fear-related memory. There is a great need for safe
and effective interventions since even specialized dental
treatments programs, as applied in dental fear clinics,
generally fail to alleviate dental anxiety to a clinically
significant degree in a significant proportion of the
patients [14].
Dental anxiety has been found to exert a great impact
on the quality of daily life because of a vicious cycle of
declining psychosocial functioning related to anxiety and
embarrassment, and severe pain and deteriorating oral
health-related problems due to inadequate dental care
[20, 67, 68]. Therefore, targeting the reconsolidation of
disturbing memories of aversive experiences in which
dental anxiety are rooted, with the purpose of helping to
transform these into less disturbing memories, may pave
the way to a higher treatment success rate in people
with high levels of dental anxiety. This would offer sup-
port for routinely prescribing of propranolol in patients
who are highly fearful of undergoing a dental extraction.
Trial status
The trial is ongoing and currently recruiting.
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